Redox-sensitive, PEG-shielded carboxymethyl PEI nanogels silencing MicroRNA-21, sensitizes resistant ovarian cancer cells to cisplatin

Javanmardi, Sanaz; Tamaddon, Ali Mohammad; Aghamaali, Mahmoud Reza; Ghahramani, Ladan; Abolmaali, Samira Sadat

doi:10.1016/j.ajps.2018.10.006

Cited by 23 publications

(19 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intracellular liberation of RNA payloads from the vectors is the prerequisite for effective transfection and genome editing. The bio-stimuli triggered degradation of the nanovectors is a potential strategy for rapid RNA molecule release [ 53 ]. Liu et al [ 54 ] reported a reducible lipid nanoparticle (BAMEA-O16B) to encapsulate Cas9 mRNA and sgRNA for swift and effective genome editing ( Figure 7 A).…”

Section: Non-viral Nanovectors For Crispr/cas9 Deliverymentioning

confidence: 99%

CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications

2021

View full text Add to dashboard Cite

The clustered regularly interspaced short palindromic repeats (CRISPR)/associated protein 9 (CRISPR/Cas9) systems have emerged as a robust and versatile genome editing platform for gene correction, transcriptional regulation, disease modeling, and nucleic acids imaging. However, the insufficient transfection and off-target risks have seriously hampered the potential biomedical applications of CRISPR/Cas9 technology. Herein, we review the recent progress towards CRISPR/Cas9 system delivery based on viral and non-viral vectors. We summarize the CRISPR/Cas9-inspired clinical trials and analyze the CRISPR/Cas9 delivery technology applied in the trials. The rational-designed non-viral vectors for delivering three typical forms of CRISPR/Cas9 system, including plasmid DNA (pDNA), mRNA, and ribonucleoprotein (RNP, Cas9 protein complexed with gRNA) were highlighted in this review. The vector-derived strategies to tackle the off-target concerns were further discussed. Moreover, we consider the challenges and prospects to realize the clinical potential of CRISPR/Cas9-based genome editing.

show abstract

Section: Non-viral Nanovectors For Crispr/cas9 Deliverymentioning

confidence: 99%

CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications

2021

View full text Add to dashboard Cite

show abstract

“…For example, Javanmardi et al. established a new plasmid delivery system, PEG2k-CMPEI-ss, which can deliver anti-miR-21 to OC cells, thereby increasing sensitivity to cisplatin ( 133 ). Moreover, accumulating evidence has demonstrated that exosomes, natural physiological nanovesicles, are useful carriers for miRNAs delivery.…”

Section: Mirna−related Therapeutic Strategiesmentioning

confidence: 99%

Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape

et al. 2021

View full text Add to dashboard Cite

Ovarian cancer (OC) is still the leading cause of death among all gynecological malignancies, despite the recent progress in cancer therapy. Immune escape and drug resistance, especially platinum-based chemotherapy, are significant factors causing disease progression, recurrence and poor prognosis in OC patients. MicroRNAs(miRNAs) are small noncoding RNAs, regulating gene expression at the transcriptional level. Accumulating evidence have indicated their crucial roles in platinum resistance. Importantly, they also act as mediators of tumor immune escape/evasion. In this review, we summarize the recent study of miRNAs involved in platinum resistance of OC and systematically analyses miRNAs involved in the regulation of OC immune escape. Further understanding of miRNAs roles and their possible mechanisms in platinum resistance and tumor escape may open new avenues for improving OC therapy.

show abstract

“…The unusual anticancer effect of miR-21-5p contradicts the general notion of its canonical oncogenic role in various cancers, including ovarian cancers. By searching related terms in PubMed, we found several studies reporting the relationship between miR-21-5p and cisplatin resistance in ovarian cancer, and all the studies demonstrate that miR-21 contributes to the development of cisplatin resistant phenotype [ 101 , 102 , 103 , 104 ]. It is of particular interest to us as three out of four studies are performed in A2780 cell line or its variants as well, which indicates a similar cellular background.…”

Section: Functional Annotation Of Premature Mirnas In Cancersmentioning

confidence: 99%

Premature MicroRNA-Based Therapeutic: A “One-Two Punch” against Cancers

Chen

Huang

et al. 2020

Cancers

View full text Add to dashboard Cite

Up-to-date knowledge regarding the biogenesis and functioning of microRNAs (miRNAs) has provided a much more comprehensive and concrete view of miRNA biology than anyone ever expected. Diverse genetic origins and biogenesis pathways leading to functional miRNAs converge on the synthesis of ≈21-nucleotide RNA duplex, almost all of which are processed from long premature sequences in a DICER- and/or DROSHA-dependent manner. Formerly, it was assumed that one mature strand of the duplex is preferentially selected for entry into the silencing complex, and the paired passenger strands (miRNA*) are subjected to degradation. However, given the consolidated evidence of substantial regulatory activity of miRNA* species, currently, this preconception has been overturned. Here, we see the caveat and opportunity toward exogenously manipulating the expression of premature miRNA, leading to simultaneous upregulation or downregulation of dual regulatory strands due to altered expressions. The caveat is the overlooked miRNA* interference while manipulating the expression of a target miRNA at the premature stage, wherein lies the opportunity. If the dual strands of a pre-miRNA function synergistically, the overlooked miRNA* interference may inversely optimize the therapeutic performance. Insightfully, targeting the premature miRNAs may serve as the “one-two punch” against diseases, especially cancers, and this has been discussed in detail in this review.

show abstract

Redox-sensitive, PEG-shielded carboxymethyl PEI nanogels silencing MicroRNA-21, sensitizes resistant ovarian cancer cells to cisplatin

Cited by 23 publications

References 69 publications

CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications

CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications

Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape

Premature MicroRNA-Based Therapeutic: A “One-Two Punch” against Cancers

Contact Info

Product

Resources

About